Armistice Capital, Llc - Jan 12, 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role: Director, 10%+ Owner
Signature: ARMISTICE CAPITAL, LLC, Name: /s/ Steven Boyd, Title: Managing Member
Stock symbol: AVTX
Transactions as of: Jan 12, 2022
Transactions value $: $452,768
Form type: 4
Date filed: 1/14/2022, 04:49 PM
Previous filing: Jan 11, 2022
Next filing: Jan 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVTX	Common Stock	Purchase	$59.8K	+57.3K	+0.13%	$1.04	45.7M	Jan 12, 2022	See Footnote	F1, F2
transaction	AVTX	Common Stock	Purchase	$314K	+313K	+0.68%	$1.00	46M	Jan 13, 2022	See Footnote	F1
transaction	AVTX	Common Stock	Purchase	$79K	+85K	+0.18%	$0.93	46.1M	Jan 14, 2022	See Footnote	F1, F3
holding	AVTX	Common Stock						412K	Jan 12, 2022	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0300 to $1.0550, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9137 to $0.9497, inclusive.
F4	These shares are directly owned by Mr. Boyd in his personal capacity.

Remarks:

Each of the Master Fund and Armistice Capital may be deemed a director by deputization of the Issuer by virtue of the fact that Steven Boyd, a representative of the Master Fund and Armistice Capital, currently serves on the Issuer's board of directors.